Continuous inhibition of serotonin-induced platelet aggregation during chronic ketanserin administration to man can be detected after plasma pH control.
Ketanserin is a well-known serotonin S2 receptor antagonist but its capacity to inhibit serotonin-induced aggregation ex vivo during chronic administration has been a matter of debate. In vitro evidence is presented that the inhibitory capacity of ketanserin is lowered by increasing plasma pH. Since the pH of plasma kept at the open air increases with time, we studied the effect of chronic administered ketanserin on serotonin-induced platelet aggregation in plasma kept at a lowered pH of 7.70, by replacing the air with 95% O2-5% CO2. Using this slightly modified technique, we could, in contrast to our previous studies, observe a complete inhibition of the serotonin-induced aggregation throughout the ketanserin treatment period.
Department of Pathophysiology, University of Leuven, (KUL), Belgium.
J
J
Arnout
M
M
van Russelt
H
H
Deckmyn
J
J
Vermylen
D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D007650:Ketanserin / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors; D012701:Serotonin / Q000494:pharmacology*
D010975:Platelet Aggregation Inhibitors; D012701:Serotonin; D007650:Ketanserin